| # | Title | Journal | Year | Citations |
|---|
| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | Autophagy | 2016 | 4,701 |
| 2 | Allergic Rhinitis and its Impact on Asthma (ARIA) 2008* | Allergy: European Journal of Allergy and Clinical Immunology | 2008 | 3,827 |
| 3 | Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma | Nature | 2012 | 2,129 |
| 4 | Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing | Nature Genetics | 2019 | 1,962 |
| 5 | EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists | Rhinology | 2012 | 1,665 |
| 6 | European Position Paper on Rhinosinusitis and Nasal Polyps 2020 | Rhinology | 2020 | 1,555 |
| 7 | Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma | Cancer Cell | 2012 | 1,551 |
| 8 | Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction | New England Journal of Medicine | 2019 | 1,485 |
| 9 | Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 | Autophagy | 2021 | 1,430 |
| 10 | Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia | New England Journal of Medicine | 2014 | 1,427 |
| 11 | Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data | BMJ: British Medical Journal | 2017 | 1,408 |
| 12 | Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis | New England Journal of Medicine | 2017 | 1,322 |
| 13 | A new taxonomy for describing and defining adherence to medications | British Journal of Clinical Pharmacology | 2012 | 1,308 |
| 14 | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | New England Journal of Medicine | 2015 | 1,261 |
| 15 | Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision | Journal of Allergy and Clinical Immunology | 2017 | 1,199 |
| 16 | EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists | Rhinology | 2012 | 1,086 |
| 17 | iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL | Blood | 2018 | 1,069 |
| 18 | Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial | Lancet, The | 2012 | 1,041 |
| 19 | Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial | Lancet, The | 2012 | 1,040 |
| 20 | Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia | Journal of Clinical Oncology | 2012 | 998 |
| 21 | International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts | Blood | 2015 | 982 |
| 22 | A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2011 | 960 |
| 23 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study | Lancet Oncology, The | 2011 | 835 |
| 24 | Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers | Journal of Allergy and Clinical Immunology | 2016 | 833 |
| 25 | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data | Blood | 2022 | 814 |
| 26 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | 2022 | 805 |
| 27 | Hypothalamic-Pituitary-Testicular Axis Disruptions in Older Men Are Differentially Linked to Age and Modifiable Risk Factors: The European Male Aging Study | Journal of Clinical Endocrinology and Metabolism | 2008 | 790 |
| 28 | Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease | Nature Genetics | 2017 | 783 |
| 29 | Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study | Allergy: European Journal of Allergy and Clinical Immunology | 2011 | 778 |
| 30 | Common genetic variants influence human subcortical brain structures | Nature | 2015 | 772 |
| 31 | EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography | Journal of the American Society of Echocardiography | 2012 | 760 |
| 32 | Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction | New England Journal of Medicine | 2011 | 734 |
| 33 | Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 | JAMA Oncology | 2022 | 719 |
| 34 | A checklist for identifying determinants of practice: A systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice | Implementation Science | 2013 | 701 |
| 35 | EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot) | European Journal of Heart Failure | 2013 | 645 |
| 36 | Plasma Endothelin-1 Levels in Septic Patients | Journal of Intensive Care Medicine | 2007 | 588 |
| 37 | Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC) | European Journal of Echocardiography | 2008 | 582 |
| 38 | Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma | New England Journal of Medicine | 2018 | 564 |
| 39 | European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions | European Journal of Heart Failure | 2016 | 538 |
| 40 | Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry | European Journal of Heart Failure | 2013 | 533 |
| 41 | The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress | Current Molecular Medicine | 2016 | 527 |
| 42 | Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) | Blood | 2012 | 520 |
| 43 | Practical guide to skin prick tests in allergy to aeroallergens | Allergy: European Journal of Allergy and Clinical Immunology | 2012 | 475 |
| 44 | Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy | Journal of Allergy and Clinical Immunology | 2013 | 461 |
| 45 | Rupatadine in allergic rhinitis and chronic urticaria | Allergy: European Journal of Allergy and Clinical Immunology | 2008 | 458 |
| 46 | Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2015 | 458 |
| 47 | ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis | Multiple Sclerosis Journal | 2018 | 458 |
| 48 | Anaphylaxis in children and adolescents: The European Anaphylaxis Registry | Journal of Allergy and Clinical Immunology | 2016 | 438 |
| 49 | Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia | Journal of Clinical Oncology | 2010 | 437 |
| 50 | Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study | Lancet Respiratory Medicine,the | 2014 | 435 |
